quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:56:09·114d
SECFiling
IN8bio Inc. logo

SEC Form SCHEDULE 13G filed by IN8bio Inc.

INAB· IN8bio Inc.
Health Care
Original source

Companies

  • INAB
    IN8bio Inc.
    Health Care

Recent analyst ratings

  • Mar 18UpdateLaidlaw$7.50
  • Aug 30UpdateH.C. Wainwright$14.00
  • Jan 24UpdateB. Riley Securities$9.00
  • Aug 24UpdateMizuho$12.00
  • Aug 23UpdateB. Riley Securities$19.00

Related

  • PR20d
    IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    SEC Form DEFA14A filed by IN8bio Inc.
  • SEC28d
    SEC Form DEF 14A filed by IN8bio Inc.
  • SEC42d
    SEC Form 10-K filed by IN8bio Inc.
  • SEC42d
    IN8bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR42d
    IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
  • SEC52d
    SEC Form SCHEDULE 13G filed by IN8bio Inc.
  • SEC55d
    SEC Form 8-K filed by IN8bio Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022